megestrol has been researched along with thalidomide in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| James, JS | 2 |
| Cipriani, G; Mazzanti, R | 1 |
| Bendini, C; Bernardi, M; Cantarini, MC; Cappa, FM; Magini, G; Santi, V; Trevisani, F; Zambruni, A | 1 |
| Lim, ST; Ong, S; Quek, R | 1 |
| Mantovani, G | 1 |
1 review(s) available for megestrol and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 trial(s) available for megestrol and thalidomide
| Article | Year |
|---|---|
Effects of the combined treatment with thalidomide, megestrol and interleukine-2 in cirrhotic patients with advanced hepatocellular carcinoma. A pilot study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Interleukin-2; Liver Cirrhosis; Liver Neoplasms; Male; Megestrol; Middle Aged; Neoplasm Staging; Pilot Projects; Survival Analysis; Survival Rate; Thalidomide; Treatment Outcome; Tremor | 2005 |
Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia.
Topics: Aged; Body Composition; Cachexia; Carnitine; Contraceptives, Oral, Hormonal; Eicosapentaenoic Acid; Endpoint Determination; Energy Metabolism; Female; Humans; Male; Medroxyprogesterone; Megestrol; Middle Aged; Motor Activity; Neoplasms; Prognosis; Thalidomide | 2010 |
4 other study(ies) available for megestrol and thalidomide
| Article | Year |
|---|---|
Wasting syndrome--affordable treatments.
Topics: Acquired Immunodeficiency Syndrome; Cachexia; Costs and Cost Analysis; Dronabinol; Exercise Therapy; Growth Hormone; Humans; Ketotifen; Medical Indigency; Megestrol; Nandrolone; Recombinant Proteins; Testosterone; Thalidomide | 1995 |
Thalidomide for wasting syndrome: progress toward compromise.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cachexia; Dose-Response Relationship, Drug; Dronabinol; Drug Costs; Drugs, Investigational; Humans; Megestrol; Sarcoma, Kaposi; Stomatitis, Aphthous; Thalidomide | 1995 |
Treatment with inhibitors of angiogenesis in advanced hepatocellular carcinoma: a new tool in our hands or simply a hope?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Carcinoma, Hepatocellular; Fibroblast Growth Factor 2; Hepatocyte Growth Factor; Humans; Interleukin-2; Liver Neoplasms; Megestrol; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Hepatocellular carcinoma--Pathological complete response to oral capecitabine, megestrol and thalidomide.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Fluorouracil; Humans; Male; Megestrol; Thalidomide; Treatment Outcome | 2006 |